Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a
specific genetic lesion, the Philadelphia chromosome, harboring the BCR-ABL oncogene …

The tyrosine kinase inhibitor Imatinib Mesylate has dramatically improved the clinical
outcome of chronic myeloid leukemia (CML) patients in the chronic phase of the disease …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

Imatinib is the therapeutic standard for newly diagnosed patients with chronic myeloid
leukemia (CML). Recent updates of the IRIS trial, a study of standard-dose imatinib in newly …

Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML).
However, whether it should be discontinued in patients who achieve sustained molecular …

Purpose Imatinib is remarkably effective in treating newly diagnosed patients with chronic
myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come …

Imatinib was discontinued in patients with chronic myeloid leukemia (CML) who gained a
complete molecular response (CMR). Of those patients with at least 12 months follow-up …

Treatment responses to imatinib vary among patients with chronic myeloid leukemia (CML),
and definitions of treatment failure and suboptimal response have been published. This …

The tyrosine kinase inhibitor imatinib mesylate (Gleevec)(formerly STI571) has proven to be
an effective and safe new therapy for patients with chronic myeloid leukemia (CML). It has …

Background The treatment options for bcr-abl positive chronic myelogenous leukemia (CML)
include chemotherapy, immune therapy, allogeneic stem cell transplantation, and molecular …